a year ago
SRPT
AnalystsMitchell KapoorMitchell Kapoor's Stock Forecasts
AnalystsMitchell Kapoor
Sectors:
Industries:
Analyst Ranking
Top 5%
#218 out of 5220 analysts
Average Return
+12.03%
Win Rate
42%135 out of 321
Risk vs Reward
Poor
Good
Mitchell Kapoor's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Alumis IncALMS | +612.04% | $3.57 | $25.42 | 2025-03-19 - 2026-03-18 | Buy |
Alumis IncALMS | +555.15% | $3.88 | $25.42 | 2025-07-24 - 2026-03-18 | Buy |
Alumis IncALMS | +554.63% | $4.54 | $29.72 | 2025-03-02 - 2026-03-02 | Buy |
Alumis IncALMS | +514.01% | $4.14 | $25.42 | 2025-04-29 - 2026-03-18 | Buy |
Alumis IncALMS | +486.64% | $4.79 | $28.10 | 2025-03-10 - 2026-03-10 | Buy |
Mitchell Kapoor Analyst Color
Get additional color on Mitchell Kapoor's coverage of popular stocks
a year ago
SRPT
2 years ago
SMMT
Mitchell Kapoor's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Crispr Therapeutics AgCRSP | 5 | Buy | $80.00 | +67.75% | Maintains | 7 months ago |
Halozyme Therapeutics IncHALO | 36 | Buy | $75.00 | +17.83% | Maintains | 7 months ago |
Ionis Pharmaceuticals IncIONS | 5 | Buy | $65.00 | -9.31% | Maintains | 8 months ago |
Alumis IncALMS | 13 | Buy | $14.00 | -44.93% | Reiterates | 8 months ago |
Korro Bio IncKRRO | 13 | Buy | $100.00 | +776.42% | Reiterates | 8 months ago |
Oruka Therapeutics IncORKA | 6 | Buy | $45.00 | +10.29% | Reiterates | 8 months ago |
Legend Biotech CorpLEGN | 39 | Buy | $75.00 | +311.86% | Reiterates | 8 months ago |
Tyra Biosciences IncTYRA | 20 | Buy | $30.00 | -21.16% | Reiterates | 9 months ago |
Summit Therapeutics IncSMMT | 14 | Buy | $44.00 | +182.05% | Reiterates | 9 months ago |
Sarepta Therapeutics IncSRPT | 16 | Sell | $10.00 | -41.72% | Downgrades | 9 months ago |
Lyell Immunopharma IncLYEL | 13 | Hold | $10.00 | -50.15% | Maintains | 9 months ago |
Verve Therapeutics IncVERV | 7 | Hold | $13.50 | +21.29% | Downgrades | 9 months ago |
Intellia Therapeutics IncNTLA | 4 | Buy | $30.00 | +127.10% | Reiterates | 9 months ago |
Instil Bio IncTIL | 16 | Buy | $125.00 | +1,398.80% | Reiterates | 9 months ago |
Boundless Bio IncBOLD | 1 | Buy | $5.00 | +327.35% | Initiates Coverage On | 10 months ago |
Avalo Therapeutics IncAVTX | 1 | Buy | $15.00 | +2.18% | Assumes | 10 months ago |
Kyverna Therapeutics IncKYTX | 7 | Buy | $5.00 | -41.45% | Upgrades | 10 months ago |
Cytomx Therapeutics IncCTMX | 3 | Buy | $5.00 | +13.64% | Reiterates | 10 months ago |
Lexeo Therapeutics IncLXEO | 8 | Buy | $15.00 | +160.64% | Maintains | 10 months ago |
Neurogene IncNGNE | 15 | Buy | $45.00 | +130.77% | Maintains | 10 months ago |
Editas Medicine IncEDIT | 1 | Buy | $3.00 | +27.66% | Initiates Coverage On | a year ago |
Cartesian Therapeutics IncRNAC | 16 | Buy | $40.00 | +501.50% | Reiterates | a year ago |
Metagenomi Therapeutics IncMGX | 9 | Buy | $7.00 | +386.11% | Maintains | a year ago |
Zura Bio LtdZURA | 6 | Hold | $3.00 | -49.92% | Maintains | a year ago |
Rani Therapeutics Holdings IncRANI | 15 | Buy | $9.00 | +656.30% | Reiterates | a year ago |
Century Therapeutics IncIPSC | 16 | Buy | $2.00 | -13.04% | Maintains | a year ago |
Abeona Therapeutics IncABEO | 2 | Buy | $15.00 | +229.67% | Reiterates | a year ago |
Rallybio CorpRLYB | 19 | Buy | $40.00 | N/A | Reiterates | a year ago |
Tc Biopharm PLCTCBP | 3 | Buy | $48.00 | N/A | Maintains | a year ago |
Carisma Therapeutics IncCARM | 11 | Buy | $5.00 | N/A | Maintains | a year ago |
Onkure Therapeutics IncOKUR | 4 | Hold | $15.00 | N/A | Reiterates | 2 years ago |
Rain Oncology IncRAIN2 | 2 | Buy | $19.00 | N/A | Maintains | 3 years ago |
Imago Biosciences IncIMGO | 4 | Hold | $36.00 | N/A | Downgrades | 3 years ago |
Aditxt IncADTX | 1 | Buy | $1,446,400,000.00 | N/A | Initiates Coverage On | 3 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.